![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
1. Banamine
2. Finadyne
3. Sch 14714 Meglumine
1. 42461-84-7
2. Flunixin Meglumin
3. Banamine
4. Sch 14714 Meglumine
5. Flumeglumine
6. Flunixin-s
7. Flunixin N-methylglucanine
8. Flunixin (meglumine)
9. Flunixin Meglumine Salt
10. Sch-14714 Meglumine
11. Nsc-759583
12. 8y3jk0jw3u
13. Finadyne
14. Chebi:76144
15. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
16. 1-deoxy-1-(methylamino)-d-glucitol 2-(2-methyl-3-(perfluoromethyl)anilino)nicotinate
17. 3-pyridinecarboxylic Acid, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-, Compd. With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
18. Banamine (veterinary)
19. Flunixin Meglumine [usan]
20. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol;2-[2-methyl-3-(trifluoromethyl)anilino]pyridine-3-carboxylic Acid
21. Smr000875279
22. Sr-05000001901
23. Einecs 255-836-0
24. Unii-8y3jk0jw3u
25. Flunixin Meglumine [usan:usp]
26. Flunixin Meglumine (usp)
27. Banamine [vetarynary] (tn)
28. Schembl43691
29. Bspbio_002558
30. 2-(alpha(sup 3),alpha(sup 3),alpha(sup 3)-trifluoro-2,3-xylidino)nicotinic Acid Compound With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
31. Mls001333159
32. Mls002153985
33. Spectrum1505113
34. Chembl1733447
35. Hms2093i10
36. Hms2234k05
37. Hms3884j07
38. Pharmakon1600-01505113
39. Flunixin Meglumine [mart.]
40. Flunixin Meglumine [usp-rs]
41. Hy-b0386
42. Flunixin Meglumine Salt [mi]
43. Mfcd01725419
44. Nsc759583
45. S2108
46. Flunixin Meglumine, >=98% (hplc)
47. Akos015895954
48. Ac-6012
49. Ccg-213338
50. Flunixin Meglumine [green Book]
51. Ks-5126
52. Nsc 759583
53. Ncgc00180889-01
54. 2-((2-methyl-3-(trifluoromethyl)-phenyl)amino)-3-pyridinecarboxylic Acid With Meglumine Compounded
55. D-glucitol, 1-deoxy-1-(methylamino)-, 2-((2-methyl-3-(trifluoromethyl)phenyl)amino)-3-pyridinecarboxylate (salt)
56. Flunixin Meglumine [usp Monograph]
57. Sw196448-3
58. Flunixin Meglumine 100 Microg/ml In Methanol
59. D04216
60. H10204
61. Ab00920714_05
62. Ab00920714_06
63. 461f847
64. Flunixin Meglumine 100 Microg/ml In Acetonitrile
65. Q-201124
66. Sr-05000001901-1
67. Sr-05000001901-3
68. Q27145782
69. Flunixin Meglumine, European Pharmacopoeia (ep) Reference Standard
70. Flunixin Meglumine, United States Pharmacopeia (usp) Reference Standard
71. Flunixin Meglumine, Pharmaceutical Secondary Standard; Certified Reference Material
72. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-(2-methyl-3-(trifluoromethyl)phenylamino)nicotinate
73. (2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentaol2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinate
74. 1-deoxy-1-(methylazaniumyl)-d-glucitol 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinate
75. 2-(.alpha.(sup 3),.alpha.(sup 3),.alpha.(sup 3)-trifluoro-2,3-xylidino)nicotinic Acid Compound With 1-deoxy-1-(methylamino)-d-glucitol (1:1)
76. 2-{[2-methyl-3-(trifluoromethyl)phenyl]amino}nicotinic Acid--1-deoxy-1-(methylamino)-d-glucitol (1/1)
Molecular Weight | 491.5 g/mol |
---|---|
Molecular Formula | C21H28F3N3O7 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 13 |
Rotatable Bond Count | 9 |
Exact Mass | 491.18793473 g/mol |
Monoisotopic Mass | 491.18793473 g/mol |
Topological Polar Surface Area | 175 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 510 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antipyretics
Drugs that are used to reduce body temperature in fever. (See all compounds classified as Antipyretics.)